Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 29, 2008, Pages 9976-9981

  Vulliez Le Normand, B ^a   Saul, F A ^a   Phalipon, A ^b,c   Belot F ^a   Guerreiro, C ^a   Mulard, L A ^a   Bentley, G A ^a  

^a CNRS   (France)

^b Institut Pasteur

^c INSERM   (France)

Author keywords

Antibody complex; Carbohydrate; Crystal structure; Polyliposaccharide; Shigellosis

Indexed keywords

CARBOHYDRATE; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F22 4; O ANTIGEN; OLIGOSACCHARIDE; PENTASACCHARIDE; RHAMNOSE; TETRASACCHARIDE;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ANTIGEN STRUCTURE; ANTIGENICITY; ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; IMMUNOGENICITY; PRIORITY JOURNAL; SEROTYPE; SHIGELLA FLEXNERI; SHIGELLA FLEXNERI SEROTYPE 2A; SHIGELLOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; BACTERIAL VACCINES; BINDING SITES, ANTIBODY; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CRYSTALLOGRAPHY, X-RAY; DYSENTERY, BACILLARY; GLYCOSYLATION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; O ANTIGENS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; SEROTYPING; SHIGELLA FLEXNERI;

ANIMALIA; PUFFINUS AURICULARIS; SHIGELLA FLEXNERI; SHIGELLA FLEXNERI 2A;

EID: 48249119924     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0801711105     Document Type: Article

References (33)

1. Niyogi SK (2005) Shigellosis. J Microbiol 43:133-143.
2. Kotloff KL, et al. (1999) Global burden of Shigella infections: Implications for vaccine development and implementation of control strategies. Bull World Health Organ 77:651- 666.
3. Jennison AV, Verma NK (2004) Shigella flexneri infection: Pathogenesis and vaccine development. FEMS Microbiol Rev 28:43-58.
4. Lindberg AA, Karnell A, Weintraub A (1991) The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infect Dis 13:S279-284.
5. Allison GE, Verma NK (2000) Serotype-converting bacteriophages and O-antigen modification in Shigella flexneri. Trends Microbiol 8:17-23.
6. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB (2007) Clinical trials of Shigella vaccines: Two steps forward and one step back on a long, hard road. Nat Rev Microbiol 5:540-553.
7. Passwell JH, et al. (2001) Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 69:1351-1357.
8. Passwell JH, et al. (2003) Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr Infect Dis J 22:701-706.
9. Belot F, Wright K, Costachel C, Phalipon A, Mulard LA (2004) Blockwise approach to fragments of the O-specific polysaccharide of Shigella flexneri serotype 2a: Convergent synthesis of a decasaccharide representative of a dimer of the branched repeating unit. J Org Chem 69:1060-1074.
10. Wright K, Guerreiro C, Laurent I, Baleux F, Mulard LA (2004) Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease. Org Biomol Chem 2:1518-1527.
11. Belot F, Guerreiro C, Baleux F, Mulard LA (2005) Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection. Chemistry 11:1625-1635.
12. Phalipon A, et al. (2006) Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: Implications for the development of a chemically defined glycoconjugate vaccine. J Immunol 176:1686-1694.
13. Mulard LA, Phalipon A (2008) From epitope characterization to the design of semi-synthetic glycoconjugate vaccines against Shigella flexneri 2a infection. Carbohydrate-based vaccines. ACS Symp Ser no 989, ed Roy R (Am Chem Soc, Washington, DC), pp 105-136.
14. Frank M, Lutteke T, von der Lieth CW (2007) GlycoMapsDB: A database of the accessible conformational space of glycosidic linkages. Nucleic Acids Res 35:287-290.
15. Collaborative Computing Project 4 (1994) The CCP4 Suite: Programs for protein crystallography. Acta Crystallogr D 50:760-763.
16. Kabat EA (1966) The nature of an antigenic determinant. J Immunol 97:1-11.
17. Cisar J, Kabat EA, Dorner MM, Liao J (1975) Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran. J Exp Med 142:435-459.
18. Padlan EA, Kabat EA (1988) Model-building study of the combining sites of two antibodies to alpha (1→6)dextran. Proc Natl Acad Sci USA 85:6885-6889.
19. Cygler M, Rose DR, Bundle DR (1991) Recognition of a cell-surface oligosaccharide of pathogenic Salmonella by an antibody Fab fragment. Science 253:442-445.
20. Villeneuve S, et al. (2000) Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: Molecular basis for serotype specificity. Proc Natl Acad Sci USA 97:8433-8438.
21. Vyas NK, et al. (2002) Molecular recognition of oligosaccharide epitopes by a monoclonal Fab specific for Shigella flexneri Y lipopolysaccharide: X-ray structures and thermodynamics. Biochemistry 41:13575-13586.
22. Cygler M, Wu S, Zdanov A, Bundle DR, Rose DR (1993) Recognition of a carbohydrate antigenic determinant of Salmonella by an antibody. Biochem Soc Trans 21:437-441.
23. Evans SV, et al. (1995) Evidence for the extended helical nature of polysaccharide epitopes. The 2.8 A resolution structure and thermodynamics of ligand binding of an antigen binding fragment specific for a-(2→8)- polysialic acid. Biochemistry 34:6737-6744.5.
24. Clement MJ, et al. (2003) Conformational studies of the O-specific polysaccharide of Shigella flexneri 5a and of four related synthetic pentasaccharide fragments using NMR and molecular modeling. J Biol Chem 278:47928-47936.
25. Goebel WF (1939) Studies on antibacterial immunity induced by artificial antigens. J Exp Med 69:353-364.
26. Benaissa-Trouw B, et al. (2001) Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect Immun 69:4698-4701.
27. Pozsgay V, et al. (1999) Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci USA 96:5194-5197.
28. Laferriere CA, Sood RK, de Muys JM, Michon F, Jennings HJ (1998) Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: Length stabilization of opsonophagocytic conformational polysaccharide epitopes. Infect Immun 66:2441-2446.
29. Kabsch W (1989) Evaluation of single crystal x-ray diffraction data from a position-sensitive detector. J Appl Crystallogr 21:916-924.
30. Navaza J (2001) Implementation of molecular replacement in AMoRe. Acta Crystallogr D 57:1367-1372.
31. McCoy AJ (2007) Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D 63:32-41.
32. Pannu NS, Murshudov GN, Dodson EJ, Read RJ (1998) Incorporation of prior phase information strengthens maximum-likelihood structure refinement. Acta Crystallogr D 54:1285-1294.
33. Perrakis A, Sixma TK, Wilson KS, Lamzin VS (1997) wARP: Improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models. Acta Crystallogr D 53:448-455.